ADDICTION MEDICINE BOARD EXAM PREP
Register Now – Start Anytime!
- Earn up to 103 AMA PRA Category 1 CME Credits™, including 24 ABPN®-Approved Self-Assessment Category 1 Credits
- Gets you ready with a deep QBank of 1300+ practice questions in board format
- Enhances your learning with high-yield online videos presented by board-focused faculty
- Saves time by following the ABPM Addiction Medicine board exam topic blueprint
- Fits your busy schedule with anytime, anywhere access
- Includes detailed, illustrated study guide
- Guarantees you′ll pass with The Triple Trust Guarantee
The Pass Rate for the ABPM 2022 Addiction Medicine Certification exam is 83%.
Compare to exam takers who prepared with The Pass Machine:
In 2022, The Pass Machine Addiction Medicine Board Review clients achieved a 98% pass rate on the Certification exam!
Why Take Chances?
In 2022, 1 in 8 failed the ABPM Board Exam in Addiction Medicine. Play it safe – brush up with The Pass Machine board prep.
Two Pathways to AM Certification
Dr. Jack’s article outlines both the Traditional Certification Pathway and the Clinical Practice Pathway to ABPM board certification.
110% Pass Guaranteed
#1 Guarantee in Board Prep for Physicians! The Triple Trust Guarantee means zero risk for you.
What do I do if I fail the Addiction Medicine Boards?
The first thing you should do is just take it easy, sleep on it. Give yourself a few days, a week or two to come to terms with what has happened. Your next exam is six months to a year away. Dr. Jack has more advice in this video, What Do You Do If You Fail Your Medical Board Exam?
ABPM Addiction Medicine Initial Certification Examination Scoring and Format
The computer-delivered Addiction Medicine Certification Examination primarily consists of 200 questions delivered in four one-hour time blocks administered over four hours and thirty minutes, including a 15-minute tutorial and a 15-minute break.
Addiction Medicine Examination questions are all multiple-choice, single-best–answer with four or five possible responses. Questions may contain a clinical vignette, an experimental or epidemiological observation, a definition or classification, an administrative problem, an application of a principle or regulation, or any situation which might be faced by a Specialist in practice.
All questions are weighted equally. You will find it to your advantage to answer all questions; there is no penalty for an incorrect answer, i.e., wrong answers are not subtracted from right answers and there is no advantage in leaving a question unanswered.
The ABPM Addiction Medicine Initial Certification Examination consists of single-best-answer multiple-choice questions.
Example of a single-best-answer multiple-choice question format:
A 44-year-old woman presents with an alcohol use disorder. She tells you she previously failed treatment with disulfiram prescribed by her internist. You prescribe naltrexone, and after 8 weeks of treatment, she happily reports a significant decrease in alcohol intake. You recall studying that people with this certain gene variant respond better to naltrexone treatment. Which allele would cause a patient to respond better to this treatment?
◯ A. Dopamine beta–hydroxylase
◯ B. Human dopamine D2 receptor E8 A/A
◯ C. Ankyrin repeat and kinase domain containing 1 rs1800497
◯ D. Dopamine active transporter 1 10/10 repeat homozygotes
◯ E. Opioid receptor mu 1 A118G
The correct answer is:
E. Opioid receptor mu 1 A118G
Presently, the US Food and Drug Administration has approved the use of disulfiram, naltrexone, and acamprosate for the treatment of AUD. One of the most constant results of naltrexone has been the decline in heavy drinking relapse, heavy drinking days, overall drinking, and alcohol craving. It has been noted that therapeutic responses to naltrexone in AUD are regulated by variations at the mu-opioid receptor gene locus (OPRM1). There are certain alcohol-dependent individuals who respond better to naltrexone treatment and they would be carriers of the OPRM1 118G allele. People low on dopamine beta-hydroxylase exhibit lack of disulfiram effects on their cocaine use while those with the Human dopamine D2 receptor E8 A/A genotype were noted to need higher doses of tiapride for alcohol use disorder, as well as increased depression and anxiety upon admission and 2 weeks after admission. Carriers of the ANKK1 rs1800497 T allele showed fewer cocaine-positive urines during the disulfiram pharmacotherapy while dopamine active transporter 1 10/10 repeat homozygotes do not reduce drinking in response to naltrexone.
Patriquin MA, Bauer IE, Soares JC, Graham DP, Nielsen DA. Addiction pharmacogenetics. Psychiatric Genetics. 2015;25(5):181-193. doi:10.1097/ypg.0000000000000095. Bilbao A, Robinson JE, Heilig M, et al. A Pharmacogenetic Determinant of Mu–Opioid Receptor Antagonist Effects on Alcohol Reward and Consumption: Evidence from Humanized Mice. Biological Psychiatry. 2015;77(10):850-858. doi:10.1016/j.biopsych.2014.08.021. Medications Development Program. November 2017. https://www.niaaa.nih.gov/research/major–initiatives/medications–development–program.